Natixis Advisors’s Cellebrite CLBT Stock Holding History

Natixis Advisors’s Portfolio CLBT Stock Details CLBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-24,131	Closed	-$469K	–	1614
2025 Q1	$469K	Buy	+24,131	New	+$508K	﹤0.01%	1468

Other funds holding CLBT

TWCM

True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return

Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Pertento Partners London, United Kingdom $1.86B AUM 53.86% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Natixis Advisors's CLBT Position: Q2 2025 in Review

Natixis Advisors sold out of Cellebrite (CLBT) in Q2 2025, closing a stake of 24,131 shares — an estimated $469K sold.

Natixis Advisors first reported a position in CLBT in Q1 2025 and held it in 1 quarter. The position peaked at $469K in Q1 2025. 209 funds tracked by Wall St. Rank hold CLBT as of Q2 2025.

Natixis Advisors reported no remaining Cellebrite position as of Q2 2025 after selling out during the quarter.
Natixis Advisors sold 24,131 Cellebrite shares in Q2 2025, an estimated $469K.
Natixis Advisors first reported a position in Cellebrite in Q1 2025 and held it in 1 quarter.
Natixis Advisors's Cellebrite position peaked at $469K in Q1 2025.
209 funds tracked by Wall St. Rank held Cellebrite as of Q2 2025.

Based on Natixis Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.